Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628659 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1159800 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL29007016 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4132345 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL29533375 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL23062653 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL529952 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31658232 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31486820 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL10044144 | 0.90 | TRPM8 (0.52) | TRPM8SMN1; SMN2CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | TRPM8 282/4885SMN1; SMN2 2361/4885KDM4E 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.